Business Context and Reporting Period
Company: Milestone Scientific Inc. (MLSS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2025
Business Overview: Milestone Scientific designs and commercializes computer-controlled anesthetic delivery devices for dental (CompuDent, STA) and medical (CompuFlo) markets. The company operates two segments: Dental and Medical. It relies on third-party manufacturers and has a significant international presence, including China.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2025 |
|---|---|---|
| Product Sales, Net | $2,323,466 | $4,555,886 |
| Gross Profit | $1,617,606 | $3,265,041 |
| Gross Margin | 69.6% | 71.7% |
| Net Loss | $(1,483,110) | $(3,477,696) |
| Loss Per Share (Basic/Diluted) | $(0.02) | $(0.04) |
| Cash and Cash Equivalents | $1,274,314 (as of June 30, 2025) | N/A |
| Working Capital | $3,863,158 (Current Assets $7.6M - Current Liab $3.8M) | N/A |
| Convertible Notes Payable | $800,000 (Related Party) | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Net product sales increased by 25.4% ($469,702) for the three months ended June 30, 2025, compared to the same period in 2024. This was driven by a 24.9% increase in Dental sales and a 68.9% increase in Medical sales.
- Operating Expenses: Total operating expenses decreased slightly by 2.8% ($89,390) for the quarter, primarily due to a significant reduction in Research and Development (R&D) expenses ($263,179 decrease), offset by increases in SG&A related to professional fees and royalties.
- Net Loss Improvement: The company reported a net loss of $1.48M for the quarter, compared to a net income of $223,638 in the prior year quarter. The prior year income was significantly boosted by a one-time $1.98M gain on the sale of New Jersey net operating losses (NOLs), which did not recur in 2025.
- Cash Flow: Net cash used in operating activities increased significantly to $2.77M for the six months ended June 30, 2025, compared to $0.43M in the prior year period, reflecting higher operating losses and changes in working capital.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the filing date due to recurring losses, an accumulated deficit of $131.5M, and the need for additional capital.
- Capital Needs: The company is actively seeking additional funding through equity or debt financings. In April 2025, it issued $800,000 in convertible notes to related parties (directors).
- Strategic Shifts: R&D expenses dropped significantly as the company decided to delay development of the next-generation STA Single Tooth Anesthesia System. Management is focusing on commercializing existing products and expanding the CompuFlo medical device footprint.
- Risk Factors:
- Supply Chain: Reliance on informal arrangements with third-party manufacturers; termination could materially harm operations.
- Trade Policy: Exposure to U.S. tariffs and trade policies, particularly regarding components sourced from China.
- Concentration: E-commerce accounted for 53% of net product sales in Q2 2025. One international distributor accounted for 10% of sales.
- Unusual Items: The prior year's net income was distorted by a non-recurring $1.98M gain from the sale of NOLs. No such gain occurred in 2025.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for raising additional capital given the "substantial doubt" going concern warning and cash burn rate of ~$2.8M over six months.
- Convertible Note Terms: Review the specific conversion terms of the $800,000 related-party notes issued in April 2025, including the floor price ($0.50) and potential dilution.
- Inventory Valuation: Confirm the $1.1M allowance for slow-moving medical finished goods (CompuFlo) and assess the risk of further write-downs if adoption does not accelerate.
- Manufacturing Stability: Assess the risk associated with the lack of long-term contracts with third-party manufacturers for core products.
- Revenue Quality: Analyze the sustainability of the 53% revenue concentration from E-commerce and the impact of potential changes in online payment processing or logistics.